U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H15NO7P2
Molecular Weight 263.1226
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OLPADRONIC ACID

SMILES

CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=UGEPSJNLORCRBO-UHFFFAOYSA-N
InChI=1S/C5H15NO7P2/c1-6(2)4-3-5(7,14(8,9)10)15(11,12)13/h7H,3-4H2,1-2H3,(H2,8,9,10)(H2,11,12,13)

HIDE SMILES / InChI

Molecular Formula C5H15NO7P2
Molecular Weight 263.1226
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Olpadronate, a nitrogenated bisphosphonate that can inhibit bone resorption. Although it shares the therapeutic and pharmacological properties of pamidronate and alendronate, it has a greater dosage amplitude, more predictable effects, and greater digestive tolerability than other bisphosphates. Clinical trials have shown that the oral olpadronate was well tolerated and effective in the treatment of Paget's disease. In addition, the drug is ongoing in phase II clinical trials in the Netherlands. This clinical trial has to assess the efficacy of the intravenous drug in decreasing the average back pain intensity from baseline.

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
Paget's disease: olpadronate was given orally in doses of 100 to 200 mg/day. Initial dose and/or increment of the dose during treatment were decided accordingly to the biochemical response Olpadronate intra venous in chronic low back pain: 20 mg and 40 mg
Route of Administration: Other
Substance Class Chemical
Record UNII
874HHB2V3S
Record Status Validated (UNII)
Record Version